KDM6B regulates the differentiation of cancer stem cells via activating distinct target genes, and may contribute to the pathogenesis of T-ALL, acute myeloid leukemia, breast cancer, Hodgkin’s Lymphoma and Glioblastoma (27, 83, 94, 104, 106–108). Here, KDM6B is linked to breast cancer.